Prosecution Insights
Last updated: April 19, 2026
Application No. 17/969,419

COLORIMETRIC DETECTION OF NUCLEIC ACIDS

Final Rejection §102§112
Filed
Oct 19, 2022
Examiner
CHUNDURU, SURYAPRABHA
Art Unit
1681
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Life Technologies Corporation
OA Round
2 (Final)
53%
Grant Probability
Moderate
3-4
OA Rounds
4y 0m
To Grant
70%
With Interview

Examiner Intelligence

Grants 53% of resolved cases
53%
Career Allow Rate
377 granted / 710 resolved
-6.9% vs TC avg
Strong +17% interview lift
Without
With
+17.2%
Interview Lift
resolved cases with interview
Typical timeline
4y 0m
Avg Prosecution
58 currently pending
Career history
768
Total Applications
across all art units

Statute-Specific Performance

§101
4.2%
-35.8% vs TC avg
§103
29.6%
-10.4% vs TC avg
§102
30.8%
-9.2% vs TC avg
§112
17.8%
-22.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 710 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION 1. The Applicant’s response to the office action filed on November 24, 2025 is acknowledged. Status of the Application 2. Claims 1-15 are pending under examination. Claims 16-20 were withdrawn as being drawn to nonelected group. The Applicant’s arguments have been fully considered and found persuasive in-part for the following reasons. Objection to the Specification-withdrawn 3. The objection to the specification has been withdrawn in view of the amendment. Claim Rejections - 35 USC § 112-Withdrawn 4. The rejection of claims 2-6 and 15 under 35 USC 112(b) has been withdrawn in view of the amendment. Claim Rejections - 35 USC § 102-Maintained 5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-15 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Ismagilov et al. (US 2018/0321137). Ismagilov et al. teach a detection reagent of claim 1, 9-10, 14, for colorimetric detection of a nucleic acid amplification reaction, comprising two or more metal indicators, a buffer comprising said detection reagent and a kit comprising said detection reagent (para 0032, 0070, 0110, 0242, 0277, 0305). With reference to claim 2, Ismagilov et al. teach that the two or more metal indicators are selected from the group consisting of: Eriochrome™ Black t, hydroxynaphthol blue (HNB), thymolphthalein complexone, methylthymol blue, xylidyl Blue I, xylidyl Blue II, calcein, copper sulfate (CuSO4) and calmagite (para 0032, 0110, 0242, 0277, 0054). With reference to claims 3-4, Ismagilov et al. teach that the two or more metal indicators comprise HNB and calmagite or the two or more metal indicators consist essentially of HNB and calmagite (para 0032, 0242, 0277, 0054). With reference to claims 5-6, Ismagilov et al. teach that the molar ratio of HNB to calmagite is between about 0.5:2 to about 2:0.5 or 1:1 (para 0242, 0277, 0070). With reference to claim 7, Ismagilov et al. teach that the amplification reaction is an isothermal amplification reaction selected from the group consisting of: a loop-mediated isothermal amplification (LAMP) reaction, a helicase displacement amplification (HPA) reaction, a strand displacement amplification, a recombinase polymerase amplification reaction, a nicking enzyme amplification reaction (NEAR), an exponential amplification reaction (EXPAR), a rolling circle amplification (RCA) reaction and a nucleic acid sequence-based amplification (NASBA) reaction (para 0026-0027, 0236). With reference to claim 8, Ismagilov et al. teach that the amplification reaction is loop- mediated isothermal amplification (LAMP) (para 0026-0027). With reference to claims 11-12, Ismagilov et al. teach that the nucleic acid amplification buffer provides a pH between about 7 and about 10 in the nucleic acid amplification reaction (para 0070). With reference to claim 13, Ismagilov et al. teach that the nucleic acid amplification reaction further comprising one or more reagents selected from the group consisting of: one or more amplification primers, one or more polymerases, one or more buffers, and one or more dNTPs (para 0263, 0305). With reference to claim 15, Ismagilov et al. teach that a kit comprising the detection reagent and the kit comprising one or more reagents selected from the group consisting of: one or more amplification primers, one or more polymerases, one or more buffers, and one or more dNTPs (para 0263, 0305). For all the above the claims are anticipated. Response to Arguments: With reference to the rejection of claims 1-15 under 35 USC 102(a)(1) as being anticipated by Ismagilov, the Applicant’s arguments have been fully considered and found unpersuasive. With reference to the Applicant’s arguments drawn to no teaching of amplification reaction comprising two or more indicators and citing para 0053-0054 and 0242 to support their arguments, the arguments were found unpersuasive. As discussed in the rejection, Ismagilov et al. teach an amplification reaction comprising two or three metal indicators (para 0305 (example 5), 0032, 0070, 0110). The Applicant’s arguments drawn to para 0053-0054 and 0242 have been found unpersuasive because the cited paragraphs teach the wavelength detection of said indicators wherein wavelength of two-color combination teaches use of two indicators in a ratio as recited in the claims. For all the above the rejection has been maintained. 6. The rejection of claims under 35 USC 102(a)(1) as being anticipated by Gee et al. has been withdrawn in view of persuasive arguments drawn to amplification reaction. Conclusion No claims are allowable. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SURYAPRABHA CHUNDURU whose telephone number is (571)272-0783. The examiner can normally be reached 8.00am-4.30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gary Benzion can be reached at 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Suryaprabha Chunduru Primary Examiner Art Unit 1681 /SURYAPRABHA CHUNDURU/Primary Examiner, Art Unit 1681
Read full office action

Prosecution Timeline

Oct 19, 2022
Application Filed
Aug 22, 2025
Non-Final Rejection — §102, §112
Nov 24, 2025
Response Filed
Feb 24, 2026
Final Rejection — §102, §112
Mar 30, 2026
Interview Requested
Apr 06, 2026
Applicant Interview (Telephonic)
Apr 07, 2026
Examiner Interview Summary
Apr 13, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12601003
METHOD FOR SELECTING POLYNUCLEOTIDES BASED ON ENZYME INTERACTION DURATION
2y 5m to grant Granted Apr 14, 2026
Patent 12577563
METHODS FOR MULTIPLEXING RECOMBINASE POLYMERASE AMPLIFICATION
2y 5m to grant Granted Mar 17, 2026
Patent 12577606
Gene target region enrichment method and kit
2y 5m to grant Granted Mar 17, 2026
Patent 12553044
METHYLATION DETECTION AND ANALYSIS OF MAMMALIAN DNA
2y 5m to grant Granted Feb 17, 2026
Patent 12534756
Method and system for the amplification of a nucleic acid
2y 5m to grant Granted Jan 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
53%
Grant Probability
70%
With Interview (+17.2%)
4y 0m
Median Time to Grant
Moderate
PTA Risk
Based on 710 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month